世界の代償性肝硬変C型市場2020:企業別、地域別、種類・用途別

【英語タイトル】Global Compensated Cirrhosis Type C Market 2020 by Company, Regions, Type and Application, Forecast to 2025

GlobalInfoResearchが出版した調査資料(GIR20AG06479)・商品コード:GIR20AG06479
・発行会社(調査会社):GlobalInfoResearch
・発行日:2020年7月
・ページ数:101
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医薬品・治療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥365,400見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥548,100見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、代償性肝硬変C型の世界市場を広く調査・分析し、今後の市場展望をまとめております。代償性肝硬変C型の種類別市場規模(拮抗薬、抗ウイルス薬、コルチコステロイド、キレート剤)、用途別市場規模(小売薬局、病院薬局、オンライン薬局、ドラッグストア)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。
・市場概要
・企業情報(販売量、市場シェア、製品概要、SWOT分析):Gilead Sciences, Inc.、Cadila Healthcare Ltd、Intercept Pharmaceuticals, Inc.、AbbVie Inc.、Alnylam Pharmaceuticals Inc.、Novartis International AG、Pfizer Inc.、Eli Lilly and Company、Novo Nordisk A/S、Sanofi S.A、Sun Pharmaceutical Industries Limited
・地域別グローバル市場分析 2015年-2020年
・代償性肝硬変C型の北米市場(アメリカ、カナダ、メキシコ)
・代償性肝硬変C型のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・代償性肝硬変C型のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・代償性肝硬変C型の南米市場(ブラジル、アルゼンチン)
・代償性肝硬変C型の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:拮抗薬、抗ウイルス薬、コルチコステロイド、キレート剤
・用途別分析:小売薬局、病院薬局、オンライン薬局、ドラッグストア
・地域別市場規模予測 2021年-2025年
・調査の結果・結論
【レポートの概要】

Market Overview
The Compensated Cirrhosis Type C market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The most likely (base case) scenario is that the global Compensated Cirrhosis Type C sales will be xx in 2020 from Compensated Cirrhosis Type C million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Compensated Cirrhosis Type C market size is expected to grow at xx% or more annually for the next five years.

This report also researches and evaluates the impact of Covid-19 outbreak on the Compensated Cirrhosis Type C industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Compensated Cirrhosis Type C and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

Market segmentation
Compensated Cirrhosis Type C market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Compensated Cirrhosis Type C market has been segmented into:
Antagonist
Antiviral Drugs
Corticosteroids
Chelating Agents

By Application, Compensated Cirrhosis Type C has been segmented into:
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
Drug Store

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Compensated Cirrhosis Type C market presented in the report. This section sheds light on the sales growth of different regional and country-level Compensated Cirrhosis Type C markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Compensated Cirrhosis Type C market.

The report offers in-depth assessment of the growth and other aspects of the Compensated Cirrhosis Type C market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Compensated Cirrhosis Type C Market Share Analysis
Compensated Cirrhosis Type C competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Compensated Cirrhosis Type C sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Compensated Cirrhosis Type C sales, revenue and market share for each player covered in this report.

The major players covered in Compensated Cirrhosis Type C are:
Gilead Sciences, Inc.
Cadila Healthcare Ltd
Intercept Pharmaceuticals, Inc.
AbbVie Inc.
Alnylam Pharmaceuticals Inc.
Novartis International AG
Pfizer Inc.
Eli Lilly and Company
Novo Nordisk A/S
Sanofi S.A
Sun Pharmaceutical Industries Limited
Among other players domestic and global, Compensated Cirrhosis Type C market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

【レポートの目次】

1 Compensated Cirrhosis Type C Market Overview
1.1 Product Overview and Scope of Compensated Cirrhosis Type C
1.2 Classification of Compensated Cirrhosis Type C by Type
1.2.1 Global Compensated Cirrhosis Type C Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Compensated Cirrhosis Type C Revenue Market Share by Type in 2019
1.2.3 Antagonist
1.2.4 Antiviral Drugs
1.2.5 Corticosteroids
1.2.6 Chelating Agents
1.3 Global Compensated Cirrhosis Type C Market by Application
1.3.1 Overview: Global Compensated Cirrhosis Type C Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Retail Pharmacy
1.3.3 Hospital Pharmacy
1.3.4 Online Pharmacy
1.3.5 Drug Store
1.4 Global Compensated Cirrhosis Type C Market by Regions
1.4.1 Global Compensated Cirrhosis Type C Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Compensated Cirrhosis Type C (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Compensated Cirrhosis Type C Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Compensated Cirrhosis Type C Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Compensated Cirrhosis Type C Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Compensated Cirrhosis Type C Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Compensated Cirrhosis Type C Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: Compensated Cirrhosis Type C Industry Impact
1.5.1 COVID-19 Potential Implications for the Compensated Cirrhosis Type C
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Compensated Cirrhosis Type C
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Gilead Sciences, Inc.
2.1.1 Gilead Sciences, Inc. Details
2.1.2 Gilead Sciences, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Gilead Sciences, Inc. SWOT Analysis
2.1.4 Gilead Sciences, Inc. Product and Services
2.1.5 Gilead Sciences, Inc. Compensated Cirrhosis Type C Revenue, Gross Margin and Market Share (2018-2019)
2.2 Cadila Healthcare Ltd
2.2.1 Cadila Healthcare Ltd Details
2.2.2 Cadila Healthcare Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Cadila Healthcare Ltd SWOT Analysis
2.2.4 Cadila Healthcare Ltd Product and Services
2.2.5 Cadila Healthcare Ltd Compensated Cirrhosis Type C Revenue, Gross Margin and Market Share (2018-2019)
2.3 Intercept Pharmaceuticals, Inc.
2.3.1 Intercept Pharmaceuticals, Inc. Details
2.3.2 Intercept Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Intercept Pharmaceuticals, Inc. SWOT Analysis
2.3.4 Intercept Pharmaceuticals, Inc. Product and Services
2.3.5 Intercept Pharmaceuticals, Inc. Compensated Cirrhosis Type C Revenue, Gross Margin and Market Share (2018-2019)
2.4 AbbVie Inc.
2.4.1 AbbVie Inc. Details
2.4.2 AbbVie Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 AbbVie Inc. SWOT Analysis
2.4.4 AbbVie Inc. Product and Services
2.4.5 AbbVie Inc. Compensated Cirrhosis Type C Revenue, Gross Margin and Market Share (2018-2019)
2.5 Alnylam Pharmaceuticals Inc.
2.5.1 Alnylam Pharmaceuticals Inc. Details
2.5.2 Alnylam Pharmaceuticals Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Alnylam Pharmaceuticals Inc. SWOT Analysis
2.5.4 Alnylam Pharmaceuticals Inc. Product and Services
2.5.5 Alnylam Pharmaceuticals Inc. Compensated Cirrhosis Type C Revenue, Gross Margin and Market Share (2018-2019)
2.6 Novartis International AG
2.6.1 Novartis International AG Details
2.6.2 Novartis International AG Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Novartis International AG Product and Services
2.6.4 Novartis International AG Compensated Cirrhosis Type C Revenue, Gross Margin and Market Share (2018-2019)
2.7 Pfizer Inc.
2.7.1 Pfizer Inc. Details
2.7.2 Pfizer Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Pfizer Inc. Product and Services
2.7.4 Pfizer Inc. Compensated Cirrhosis Type C Revenue, Gross Margin and Market Share (2018-2019)
2.8 Eli Lilly and Company
2.8.1 Eli Lilly and Company Details
2.8.2 Eli Lilly and Company Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Eli Lilly and Company Product and Services
2.8.4 Eli Lilly and Company Compensated Cirrhosis Type C Revenue, Gross Margin and Market Share (2018-2019)
2.9 Novo Nordisk A/S
2.9.1 Novo Nordisk A/S Details
2.9.2 Novo Nordisk A/S Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Novo Nordisk A/S Product and Services
2.9.4 Novo Nordisk A/S Compensated Cirrhosis Type C Revenue, Gross Margin and Market Share (2018-2019)
2.10 Sanofi S.A
2.10.1 Sanofi S.A Details
2.10.2 Sanofi S.A Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Sanofi S.A Product and Services
2.10.4 Sanofi S.A Compensated Cirrhosis Type C Revenue, Gross Margin and Market Share (2018-2019)
2.11 Sun Pharmaceutical Industries Limited
2.11.1 Sun Pharmaceutical Industries Limited Details
2.11.2 Sun Pharmaceutical Industries Limited Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Sun Pharmaceutical Industries Limited Product and Services
2.11.4 Sun Pharmaceutical Industries Limited Compensated Cirrhosis Type C Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Compensated Cirrhosis Type C Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Compensated Cirrhosis Type C Players Market Share
3.2.2 Top 10 Compensated Cirrhosis Type C Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Compensated Cirrhosis Type C Revenue and Market Share by Regions
4.2 North America Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
4.3 Europe Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
4.5 South America Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
5 North America Compensated Cirrhosis Type C Revenue by Countries
5.1 North America Compensated Cirrhosis Type C Revenue by Countries (2015-2020)
5.2 USA Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
5.3 Canada Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
5.4 Mexico Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
6 Europe Compensated Cirrhosis Type C Revenue by Countries
6.1 Europe Compensated Cirrhosis Type C Revenue by Countries (2015-2020)
6.2 Germany Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
6.3 UK Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
6.4 France Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
6.5 Russia Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
6.6 Italy Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Compensated Cirrhosis Type C Revenue by Countries
7.1 Asia-Pacific Compensated Cirrhosis Type C Revenue by Countries (2015-2020)
7.2 China Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
7.3 Japan Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
7.4 Korea Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
7.5 India Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
8 South America Compensated Cirrhosis Type C Revenue by Countries
8.1 South America Compensated Cirrhosis Type C Revenue by Countries (2015-2020)
8.2 Brazil Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
8.3 Argentina Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Compensated Cirrhosis Type C by Countries
9.1 Middle East & Africa Compensated Cirrhosis Type C Revenue by Countries (2015-2020)
9.2 Saudi Arabia Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
9.3 UAE Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
9.4 Egypt Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
9.5 South Africa Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Compensated Cirrhosis Type C Revenue and Market Share by Type (2015-2020)
10.2 Global Compensated Cirrhosis Type C Market Forecast by Type (2019-2024)
10.3 Antagonist Revenue Growth Rate (2015-2025)
10.4 Antiviral Drugs Revenue Growth Rate (2015-2025)
10.5 Corticosteroids Revenue Growth Rate (2015-2025)
10.6 Chelating Agents Revenue Growth Rate (2015-2025)
11 Global Compensated Cirrhosis Type C Market Segment by Application
11.1 Global Compensated Cirrhosis Type C Revenue Market Share by Application (2015-2020)
11.2 Compensated Cirrhosis Type C Market Forecast by Application (2019-2024)
11.3 Retail Pharmacy Revenue Growth (2015-2020)
11.4 Hospital Pharmacy Revenue Growth (2015-2020)
11.5 Online Pharmacy Revenue Growth (2015-2020)
11.6 Drug Store Revenue Growth (2015-2020)
12 Global Compensated Cirrhosis Type C Market Size Forecast (2021-2025)
12.1 Global Compensated Cirrhosis Type C Market Size Forecast (2021-2025)
12.2 Global Compensated Cirrhosis Type C Market Forecast by Regions (2021-2025)
12.3 North America Compensated Cirrhosis Type C Revenue Market Forecast (2021-2025)
12.4 Europe Compensated Cirrhosis Type C Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Compensated Cirrhosis Type C Revenue Market Forecast (2021-2025)
12.6 South America Compensated Cirrhosis Type C Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Compensated Cirrhosis Type C Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables
Table 1. Global Compensated Cirrhosis Type C Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Compensated Cirrhosis Type C by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Compensated Cirrhosis Type C Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Compensated Cirrhosis Type C Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Compensated Cirrhosis Type C Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Gilead Sciences, Inc. Corporate Information, Location and Competitors
Table 7. Gilead Sciences, Inc. Compensated Cirrhosis Type C Major Business
Table 8. Gilead Sciences, Inc. Compensated Cirrhosis Type C Total Revenue (USD Million) (2017-2018)
Table 9. Gilead Sciences, Inc. SWOT Analysis
Table 10. Gilead Sciences, Inc. Compensated Cirrhosis Type C Product and Solutions
Table 11. Gilead Sciences, Inc. Compensated Cirrhosis Type C Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Cadila Healthcare Ltd Corporate Information, Location and Competitors
Table 13. Cadila Healthcare Ltd Compensated Cirrhosis Type C Major Business
Table 14. Cadila Healthcare Ltd Compensated Cirrhosis Type C Total Revenue (USD Million) (2018-2019)
Table 15. Cadila Healthcare Ltd SWOT Analysis
Table 16. Cadila Healthcare Ltd Compensated Cirrhosis Type C Product and Solutions
Table 17. Cadila Healthcare Ltd Compensated Cirrhosis Type C Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Intercept Pharmaceuticals, Inc. Corporate Information, Location and Competitors
Table 19. Intercept Pharmaceuticals, Inc. Compensated Cirrhosis Type C Major Business
Table 20. Intercept Pharmaceuticals, Inc. Compensated Cirrhosis Type C Total Revenue (USD Million) (2017-2018)
Table 21. Intercept Pharmaceuticals, Inc. SWOT Analysis
Table 22. Intercept Pharmaceuticals, Inc. Compensated Cirrhosis Type C Product and Solutions
Table 23. Intercept Pharmaceuticals, Inc. Compensated Cirrhosis Type C Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. AbbVie Inc. Corporate Information, Location and Competitors
Table 25. AbbVie Inc. Compensated Cirrhosis Type C Major Business
Table 26. AbbVie Inc. Compensated Cirrhosis Type C Total Revenue (USD Million) (2017-2018)
Table 27. AbbVie Inc. SWOT Analysis
Table 28. AbbVie Inc. Compensated Cirrhosis Type C Product and Solutions
Table 29. AbbVie Inc. Compensated Cirrhosis Type C Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. Alnylam Pharmaceuticals Inc. Corporate Information, Location and Competitors
Table 31. Alnylam Pharmaceuticals Inc. Compensated Cirrhosis Type C Major Business
Table 32. Alnylam Pharmaceuticals Inc. Compensated Cirrhosis Type C Total Revenue (USD Million) (2017-2018)
Table 33. Alnylam Pharmaceuticals Inc. SWOT Analysis
Table 34. Alnylam Pharmaceuticals Inc. Compensated Cirrhosis Type C Product and Solutions
Table 35. Alnylam Pharmaceuticals Inc. Compensated Cirrhosis Type C Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Novartis International AG Corporate Information, Location and Competitors
Table 37. Novartis International AG Compensated Cirrhosis Type C Major Business
Table 38. Novartis International AG Compensated Cirrhosis Type C Total Revenue (USD Million) (2017-2018)
Table 39. Novartis International AG SWOT Analysis
Table 40. Novartis International AG Compensated Cirrhosis Type C Product and Solutions
Table 41. Novartis International AG Compensated Cirrhosis Type C Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. Pfizer Inc. Corporate Information, Location and Competitors
Table 43. Pfizer Inc. Compensated Cirrhosis Type C Major Business
Table 44. Pfizer Inc. Compensated Cirrhosis Type C Total Revenue (USD Million) (2017-2018)
Table 45. Pfizer Inc. SWOT Analysis
Table 46. Pfizer Inc. Compensated Cirrhosis Type C Product and Solutions
Table 47. Pfizer Inc. Compensated Cirrhosis Type C Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Eli Lilly and Company Corporate Information, Location and Competitors
Table 49. Eli Lilly and Company Compensated Cirrhosis Type C Major Business
Table 50. Eli Lilly and Company Compensated Cirrhosis Type C Total Revenue (USD Million) (2017-2018)
Table 51. Eli Lilly and Company SWOT Analysis
Table 52. Eli Lilly and Company Compensated Cirrhosis Type C Product and Solutions
Table 53. Eli Lilly and Company Compensated Cirrhosis Type C Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. Novo Nordisk A/S Corporate Information, Location and Competitors
Table 55. Novo Nordisk A/S Compensated Cirrhosis Type C Major Business
Table 56. Novo Nordisk A/S Compensated Cirrhosis Type C Total Revenue (USD Million) (2017-2018)
Table 57. Novo Nordisk A/S SWOT Analysis
Table 58. Novo Nordisk A/S Compensated Cirrhosis Type C Product and Solutions
Table 59. Novo Nordisk A/S Compensated Cirrhosis Type C Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 60. Sanofi S.A Corporate Information, Location and Competitors
Table 61. Sanofi S.A Compensated Cirrhosis Type C Major Business
Table 62. Sanofi S.A Compensated Cirrhosis Type C Total Revenue (USD Million) (2017-2018)
Table 63. Sanofi S.A SWOT Analysis
Table 64. Sanofi S.A Compensated Cirrhosis Type C Product and Solutions
Table 65. Sanofi S.A Compensated Cirrhosis Type C Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 66. Sun Pharmaceutical Industries Limited Corporate Information, Location and Competitors
Table 67. Sun Pharmaceutical Industries Limited Compensated Cirrhosis Type C Major Business
Table 68. Sun Pharmaceutical Industries Limited Compensated Cirrhosis Type C Total Revenue (USD Million) (2017-2018)
Table 69. Sun Pharmaceutical Industries Limited SWOT Analysis
Table 70. Sun Pharmaceutical Industries Limited Compensated Cirrhosis Type C Product and Solutions
Table 71. Sun Pharmaceutical Industries Limited Compensated Cirrhosis Type C Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 72. Global Compensated Cirrhosis Type C Revenue (Million USD) by Players (2015-2020)
Table 73. Global Compensated Cirrhosis Type C Revenue Share by Players (2015-2020)
Table 74. Global Compensated Cirrhosis Type C Revenue (Million USD) by Regions (2015-2020)
Table 75. Global Compensated Cirrhosis Type C Revenue Market Share by Regions (2015-2020)
Table 76. North America Compensated Cirrhosis Type C Revenue by Countries (2015-2020)
Table 77. North America Compensated Cirrhosis Type C Revenue Market Share by Countries (2015-2020)
Table 78. Europe Compensated Cirrhosis Type C Revenue (Million USD) by Countries (2015-2020)
Table 79. Asia-Pacific Compensated Cirrhosis Type C Revenue (Million USD) by Countries (2015-2020)
Table 80. South America Compensated Cirrhosis Type C Revenue by Countries (2015-2020)
Table 81. South America Compensated Cirrhosis Type C Revenue Market Share by Countries (2015-2020)
Table 82. Middle East and Africa Compensated Cirrhosis Type C Revenue (Million USD) by Countries (2015-2020)
Table 83. Middle East and Africa Compensated Cirrhosis Type C Revenue Market Share by Countries (2015-2020)
Table 84. Global Compensated Cirrhosis Type C Revenue (Million USD) by Type (2015-2020)
Table 85. Global Compensated Cirrhosis Type C Revenue Share by Type (2015-2020)
Table 86. Global Compensated Cirrhosis Type C Revenue Forecast by Type (2021-2025)
Table 87. Global Compensated Cirrhosis Type C Revenue by Application (2015-2020)
Table 88. Global Compensated Cirrhosis Type C Revenue Share by Application (2015-2020)
Table 89. Global Compensated Cirrhosis Type C Revenue Forecast by Application (2021-2025)
Table 90. Global Compensated Cirrhosis Type C Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Compensated Cirrhosis Type C Picture
Figure 2. Global Compensated Cirrhosis Type C Revenue Market Share by Type in 2019
Figure 3. Antagonist Picture
Figure 4. Antiviral Drugs Picture
Figure 5. Corticosteroids Picture
Figure 6. Chelating Agents Picture
Figure 7. Compensated Cirrhosis Type C Revenue Market Share by Application in 2019
Figure 8. Retail Pharmacy Picture
Figure 9. Hospital Pharmacy Picture
Figure 10. Online Pharmacy Picture
Figure 11. Drug Store Picture
Figure 12. Global Compensated Cirrhosis Type C Revenue (USD Million) and Growth Rate (2015-2025)
Figure 13. North America Compensated Cirrhosis Type C Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Europe Compensated Cirrhosis Type C Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Asia-Pacific Compensated Cirrhosis Type C Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. South America Compensated Cirrhosis Type C Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Middle East and Africa Compensated Cirrhosis Type C Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Compensated Cirrhosis Type C Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Compensated Cirrhosis Type C Revenue Share by Players in 2019
Figure 20. Global Top 5 Players Compensated Cirrhosis Type C Revenue Market Share in 2019
Figure 21. Global Top 10 Players Compensated Cirrhosis Type C Revenue Market Share in 2019
Figure 22. Key Players Market Share Trend
Figure 23. Global Compensated Cirrhosis Type C Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 24. Global Compensated Cirrhosis Type C Revenue Market Share by Regions (2015-2020)
Figure 25. Global Compensated Cirrhosis Type C Revenue Market Share by Regions in 2018
Figure 26. North America Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 27. Europe Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 28. Asia-Pacific Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 29. South America Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 30. Middle East and Africa Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 31. North America Compensated Cirrhosis Type C Revenue Market Share by Countries (2015-2020)
Figure 32. North America Compensated Cirrhosis Type C Revenue Market Share by Countries in 2019
Figure 33. USA Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 34. Canada Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 35. Mexico Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 36. Europe Compensated Cirrhosis Type C Revenue Market Share by Countries (2015-2020)
Figure 37. Europe Compensated Cirrhosis Type C Revenue Market Share by Countries in 2019
Figure 38. Germany Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 39. UK Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 40. France Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 41. Russia Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 42. Italy Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Compensated Cirrhosis Type C Revenue Market Share by Countries (2015-2020)
Figure 44. Asia-Pacific Compensated Cirrhosis Type C Revenue Market Share by Countries in 2019
Figure 45. China Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 46. Japan Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 47. Korea Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 48. India Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 49. Southeast Asia Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 50. South America Compensated Cirrhosis Type C Revenue Market Share by Countries (2015-2020)
Figure 51. South America Compensated Cirrhosis Type C Revenue Market Share by Countries in 2019
Figure 52. Brazil Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 53. Argentina Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 54. Middle East and Africa Compensated Cirrhosis Type C Revenue Market Share by Countries (2015-2020)
Figure 55. Middle East and Africa Compensated Cirrhosis Type C Revenue Market Share by Countries in 2019
Figure 56. Saudi Arabia Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 57. UAE Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 58. Egypt Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 59. South Africa Compensated Cirrhosis Type C Revenue and Growth Rate (2015-2020)
Figure 60. Global Compensated Cirrhosis Type C Revenue Share by Type (2015-2020)
Figure 61. Global Compensated Cirrhosis Type C Revenue Share by Type in 2019
Figure 62. Global Compensated Cirrhosis Type C Market Share Forecast by Type (2021-2025)
Figure 63. Global Antagonist Revenue Growth Rate (2015-2020)
Figure 64. Global Antiviral Drugs Revenue Growth Rate (2015-2020)
Figure 65. Global Corticosteroids Revenue Growth Rate (2015-2020)
Figure 66. Global Chelating Agents Revenue Growth Rate (2015-2020)
Figure 67. Global Compensated Cirrhosis Type C Revenue Share by Application (2015-2020)
Figure 68. Global Compensated Cirrhosis Type C Revenue Share by Application in 2019
Figure 69. Global Compensated Cirrhosis Type C Market Share Forecast by Application (2021-2025)
Figure 70. Global Retail Pharmacy Revenue Growth Rate (2015-2020)
Figure 71. Global Hospital Pharmacy Revenue Growth Rate (2015-2020)
Figure 72. Global Online Pharmacy Revenue Growth Rate (2015-2020)
Figure 73. Global Drug Store Revenue Growth Rate (2015-2020)
Figure 74. Global Compensated Cirrhosis Type C Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 75. Global Compensated Cirrhosis Type C Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 76. Global Compensated Cirrhosis Type C Revenue Market Share Forecast by Regions (2021-2025)
Figure 77. North America Compensated Cirrhosis Type C Revenue Market Forecast (2021-2025)
Figure 78. Europe Compensated Cirrhosis Type C Revenue Market Forecast (2021-2025)
Figure 79. Asia-Pacific Compensated Cirrhosis Type C Revenue Market Forecast (2021-2025)
Figure 80. South America Compensated Cirrhosis Type C Revenue Market Forecast (2021-2025)
Figure 81. Middle East and Africa Compensated Cirrhosis Type C Revenue Market Forecast (2021-2025)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel


★調査レポート[世界の代償性肝硬変C型市場2020:企業別、地域別、種類・用途別] (コード:GIR20AG06479)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の代償性肝硬変C型市場2020:企業別、地域別、種類・用途別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆